达安基因(002030) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 19,658,327.13, representing a year-on-year increase of 3.98%[7] - Operating revenue for the period was CNY 252,229,779.75, down 34.00% year-on-year[7] - Basic earnings per share were CNY 0.025, an increase of 4.17% compared to the same period last year[7] - The weighted average return on equity was 1.04%, a slight increase of 0.02% year-on-year[7] - The company's main business revenue for the first three quarters of 2019 was RMB 763,466,069.45, a decrease of 35.48% compared to RMB 1,183,352,254.69 in the same period of 2018, primarily due to the exclusion of YunKang Health from the consolidated financial statements[27] - Total operating revenue for the current period was CNY 252,229,779.75, a decrease from CNY 382,180,130.89 in the previous period[61] - Main business revenue accounted for CNY 250,754,730.34, down from CNY 381,593,076.29 year-on-year[61] - The net profit for the current period is CNY 22,860,400.73, compared to CNY 17,837,054.96 in the previous period, indicating a significant increase of about 28.4%[72] - The total profit for the current period is CNY 27,045,741.03, compared to CNY 20,768,231.25 in the previous period, marking an increase of approximately 30.5%[72] Assets and Liabilities - Total assets reached CNY 4,077,151,652.16, an increase of 11.30% compared to the end of the previous year[7] - The company's cash and cash equivalents decreased by 32.70% to RMB 259,685,108.25 from RMB 385,837,695.65, primarily due to the repayment of part of the borrowings[26] - The company's total liabilities decreased significantly, with current liabilities due within one year dropping by 80.62% to RMB 49,750,000.00 from RMB 256,734,400.00, as a result of reclassification of long-term borrowings[26] - Total liabilities decreased to CNY 1,302,964,765.68 from CNY 1,462,782,088.87, showing a reduction of approximately 10.9%[48] - The company's equity attributable to shareholders increased to CNY 2,349,007,975.94 from CNY 1,815,789,006.98, representing a growth of about 29.3%[48] - Total assets decreased to CNY 2,388,379,039.35 from CNY 2,431,707,106.22, a decline of 1.8%[58] - Total liabilities decreased to CNY 939,953,435.20 from CNY 1,050,852,073.28, a reduction of 10.5%[59] - The company reported long-term equity investments of ¥802,794,939.56, unchanged from the previous period[126] Cash Flow - Net cash flow from operating activities decreased by 61.82% to CNY 94,718,871.97[7] - Cash inflow from operating activities totaled 1,057,774,772.58, down 56.8% from 2,446,218,254.66 in the previous period[94] - Cash outflow from operating activities decreased to 862,219,328.94 from 2,255,533,016.28, a reduction of 61.8%[97] - The net cash flow from operating activities for the current period is ¥92,652,339.46, an increase of 6.5% compared to ¥86,767,906.38 in the previous period[104] Expenses - Operating costs decreased by 46.66% to RMB 372,464,796.54 from RMB 698,326,378.48, mainly due to the same reason as above[27] - Total operating costs were CNY 236,867,604.84, compared to CNY 367,136,978.74 in the previous period, indicating a significant reduction[62] - Research and development expenses decreased to CNY 18,951,920.64 from CNY 26,496,062.78, reflecting a 28.4% reduction[62] - The company reported a tax expense of CNY 4,185,340.30, up from CNY 2,931,176.29, indicating an increase of approximately 42.8%[72] Shareholder Information - The company reported a total of 81,401 shareholders at the end of the reporting period[17] - Guangzhou Zhongda Holdings Co., Ltd. held 16.63% of shares, making it the largest shareholder[17] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[22] Other Information - The company received government subsidies amounting to CNY 16,850,396.33 during the reporting period[8] - Non-recurring gains and losses totaled CNY 10,685,826.53 after tax adjustments[12] - The company reported a 100% increase in asset impairment losses, reflecting the impact of the first-time implementation of new financial standards[28] - There were no violations of external guarantees during the reporting period[34] - The company has not engaged in any research, communication, or interview activities during the reporting period, suggesting a focus on internal operations[37] - There were no significant new product developments or market expansions mentioned in the report, indicating a potential area for future growth strategies[37]